- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05385861
Nal-IRI (ONIVYDE® ) and Carboplatin in Patients With Advanced or Metastatic GEP-NET
A Phase I/II Study of Nal-IRI (ONIVYDE® ) and Carboplatin in Patients With Advanced or Metastatic Gastroenteropancreatic Poorly Differentiated Neuroendocrine Carcinoma
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Eligible patients will be treated into two cohorts.
In adaptive phase 1 cohort:
Six patients will be enrolled in safety run-in cohort of dose level 0. If less than 2 patients experience dose-limiting toxicity (DLT) in dose level 0, dose level 1 will be tested. However, if more than 1 patients experience DLT in dose level 0, dose level -1 will be tested. The MTD at which no more than 1 of the 6 patients experience DLT will be determined for the phase 2 cohort. Otherwise, additional 6 patients will be tested in the dose level -1. Based on results from safety run-in cohort, PR2D will be determined. The evaluable patients in RP2D cohort will be incorporated into phase 2 cohort for final analysis.
Dose in phase 1 cohort:
Dose level 1= onivyde 100 mg/m2 plus carboplatin AUC=4, intravenously both on day 1, q3wk Dose level 0= onivyde 80 mg/m2 plus carboplatin AUC=4, intravenously both on day 1, q3wk Dose level -1= onivyde 60 mg/m2 plus carboplatin AUC=4, intravenously both on day 1, q3wk Carboplatin dose (mg) is calculated by the Calvert formula: AUC x (eGFR + 25). Cockcroft-Gault equation: eGFR (calculated Ccr)= [(140-age) x weight x 0.85 (if female)] / (72 x serum Cr). The maximum eGFR for dose calculation is 125 ml/min.
The definition of DLT:
Following toxicities occur during the first cycle of the combination chemotherapy with nal-IRI (ONIVYDE®) and carboplatin will be considered as DLTs. Toxicities are assessed by the Common Terminology Criteria for Adverse Events version 5.0 (CTCAE v5.0).
- Grade 4 neutropenia (ANC < 500/μL) ≥3 days' duration under primary G-CSF support
- Grade 3 or higher neutropenia (ANC < 1,000/μL) with concurrent active infection requiring IV antibiotics treatment
- Grade 4 thrombocytopenia (platelet counts < 25,000/μL)
- Grade 3 thrombocytopenia (platelet counts < 50,000/μL) associated with active bleeding that transfusion is required
- Any grade 3 or higher treatment-related non-hematologic toxicity (except for anorexia/nausea, vomiting, and asthenia/fatigue)
- Any adverse drug reactions lead to more than 3 weeks delay
In Phase 2 Cohort Patients will be treated until disease progression, unacceptable toxicity or other condition meeting the treatment discontinuation criteria.
Tumor response will be assessed according to Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST v1.1) every 6 weeks.
Adverse events (AEs) will be evaluated according to the National Cancer Institute's Common Terminology Criteria for Adverse Events version 5.0 (CTCAE v5.0).
Patients sign additional consent to participate in the next generation sequencing study will be required to have extra tissue samplings at the study entry.
A follow-up visit is required approximately 30 days after treatment discontinuation. Overall survival status will be followed by clinic visit or by phone every 3 months until death or the maximum of 3 years, whichever occurs first.
Study Type
Enrollment (Anticipated)
Phase
- Phase 2
- Phase 1
Contacts and Locations
Study Contact
- Name: Bor-Rong Chen
- Phone Number: 25162 886-2-26534401
- Email: brong@nhri.edu.tw
Study Contact Backup
- Name: Nai-Jung Chiang
- Email: njchiang@nhri.edu.tw
Study Locations
-
-
-
Kaohsiung, Taiwan
- Kaohsiung Medical University Chung-Ho Memorial Hospital
-
Kaohsiung, Taiwan
- Chang-Gung Memorial Hospital, Kaohsiung
-
Linkou, Taiwan
- Chang Gung Memorial Hospital (Lin-Kou),
-
Taichung, Taiwan
- China Medical University Hospital
-
Tainan, Taiwan
- National Cheng-Kung University Hospital
-
Taipei, Taiwan
- Taipei Veterans General Hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- histologically confirmed locally advanced or metastatic gastroenteropancreatic poorly differentiated neuroendocrine carcinoma.
- patients either are chemotherapy-naive or had received adjuvant chemotherapy > 6 months before recurrence.
- at least one measurable lesion according to the RECIST version 1.1..
- patients were aged 20 to 80 years with ECOG performance status of 0 to 1.
- patients had a life expectancy ≥ 3 months.
- patients had adequate renal function with defined as serum creatinine ≤ 2 times the upper limit of normal (ULN) or eGFR (calculated Ccr) ≥ 45 mL/min.
- patients had adequate hepatic function, defined as total bilirubin ≤ 1.5 times the ULN and alanine aminotransferase ≤ 2.5 the ULN and ≤ 5 times the ULN within the setting of liver metastases.
- patients had adequate bone marrow function, defined as an absolute neutrophil count ≥ 1500/mm3, platelet count ≥ 100,000/mm3, and hemoglobin ≥ 9 g/dL.
- Normal ECG or abnormal ECG without any clinical significantly findings.
- Able to understand and sign an informed consent (or have a legal representative who is able to do so).
Exclusion Criteria:
- a history of palliative chemotherapy or disease recurrence < 6 months from the time of last adjuvant chemotherapy and/or radiotherapy.
- known hypersensitivity to liposome product, irinotecan or carboplatin.
- receipt of major surgery within the past 4 weeks before study enrollment.
- With clinically significant gastrointestinal disorder including bleeding, inflammation, occlusion or diarrhea > grade 2.
- concurrent severe infection with intravenous systemic antibiotics treatment.
- severe, uncontrolled medical condition including severe liver disease, heart disease, uncontrolled diabetes or hypertension, or pulmonary disease.
- another previous malignancy diagnosed within the past 5 years except for nonmelanoma skin cancer or stage I cervical cancer.
- active CNS metastasis defined by clinical symptoms, cerebral edema, steroid or anti-convulsant requirement, or progressive growth. Patients with a history of CNS metastasis or cord compression are allowed in the study if they have been treated and are clinically stable.
- psychiatric illness or social situation that would preclude study compliance
- women with pregnant or breast feeding (a urine pregnancy test must be performed on all patients who are of childbearing potential before entering the study, and the result must be negative).
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: nal-IRI (ONIVYDE®) and Carboplatin
|
Dose in phase 1 cohort: Dose level 1= nanoliposomal irinotecan 100 mg/m2 plus carboplatin AUC=4, intravenously both on day 1, q3wk Dose level 0= nanoliposomal irinotecan 80 mg/m2 plus carboplatin AUC=4, intravenously both on day 1, q3wk Dose level -1= nanoliposomal irinotecan 60 mg/m2 plus carboplatin AUC=4, intravenously both on day 1, q3wk Carboplatin dose (mg) is calculated by the Calvert formula: AUC x (eGFR + 25). Cockcroft-Gault equation: eGFR (calculated Ccr)= [(140-age) x weight x 0.85 (if female)] / (72 x serum Cr). The maximum eGFR for dose calculation is 125 ml/min. In Phase 2 Cohort Patients will be treated until disease progression, unacceptable toxicity or other condition meeting the treatment discontinuation criteria.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
MTD and RP2D
Time Frame: 3 Years
|
• in phase 1 cohort, to determine MTD (maximum tolerated dose) and recommended phase 2 dose (RP2D)
|
3 Years
|
tumor response rate
Time Frame: 3 Years
|
• in phase 2 cohort, to assess the objective tumor response rate
|
3 Years
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
PFS and OS
Time Frame: 3 Years
|
• to assess other efficacy variables, including disease control rate, progression free survival (PFS), and overall survival (OS)
|
3 Years
|
To explore the treatment-related adverse events as assessed by CTCAE v5.0
Time Frame: 3 Years
|
• Number of participants with treatment-related adverse events as assessed by CTCAE v5.0
|
3 Years
|
Collaborators and Investigators
Collaborators
Investigators
- Study Director: Tsang-Wu Liu, Taiwan Cooperative Oncology Group, NHRI
Study record dates
Study Major Dates
Study Start (Anticipated)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- T2222
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on GEP-NET
-
IRCCS San RaffaeleActive, not recruitingNeuroendocrine Tumors | GEP-NETItaly
-
European Institute of OncologyActive, not recruitingNeuroendocrine Tumor of Pancreas | Neuroendocrine Tumor Carcinoid | Gep NetItaly
-
Novartis PharmaceuticalsActive, not recruitingSomatostatin Receptor-positive GEP-NETKorea, Republic of
-
Rigshospitalet, DenmarkEnrolling by invitationNeuroendocrine Tumors | Neuroendocrine Carcinoma | Neuroendocrine Carcinoma Metastatic | GEP-NETDenmark
-
University Hospital, Basel, SwitzerlandSwiss National Science Foundation; Paul Scherrer Institute (PSI)RecruitingNeuroendocrine Neoplasia's (NENs) | Gastroenteropancreatic Neuroendocrine Tumour (GEP-NET)Switzerland
-
RayzeBio, Inc.RecruitingNeuroendocrine Tumors | Carcinoid Tumor | Gastroenteropancreatic Neuroendocrine Tumor | Carcinoid | GEP-NET | Gastroenteropancreatic Neuroendocrine Tumor Disease | Pancreatic NETUnited States, Canada, Belgium, Netherlands, France, Spain, Brazil
-
Debiopharm International SAActive, not recruitingAcromegaly | GEP-NETUnited Kingdom, France, Spain, Italy, Poland, Denmark, Germany, Israel
-
Novartis PharmaceuticalsCompletedWell-differentiated Non-functional NET of Thoracic Origin | Well-differentiated Non-functional NET of Gastrointestinal Origin | Well-differentiated Non-functional NET of Pancreatic Origin | Poorly-differentiated Gastroenteropancreatic Neuroendocrine CarcinomaUnited States, Italy, Spain, Japan, Belgium, Netherlands, Germany, France, Canada, Austria, United Kingdom, Australia
-
Novartis PharmaceuticalsCompletedNeuroendocrine Tumors | Advanced NET of GI Origin | Advanced NET of Lung OriginUnited States, Colombia, Italy, Taiwan, United Kingdom, Belgium, Czechia, Germany, Japan, Saudi Arabia, Canada, Netherlands, Spain, Korea, Republic of, Lebanon, Austria, China, Greece, South Africa, Thailand, Hungary, Turkey, Poland, ... and more
-
University of KonstanzCompletedTrauma Treatment | Lifeline NET | Modification of Narrative Exposure TherapyGermany
Clinical Trials on nanoliposomal irinotecan plus carboplatin
-
Charite University, Berlin, GermanyPfizer; Aventis PharmaceuticalsUnknown
-
Stony Brook UniversityUniversity of Iowa; Ipsen; Barbara Ann Karmanos Cancer InstituteCompletedGastric Cancer | Colorectal Cancer | Mesothelioma | Pseudomyxoma Peritonei | Peritoneal Cancer | Mucinous Adenocarcinoma | Primary Peritoneal Carcinoma | Mucinous TumorUnited States
-
National Health Research Institutes, TaiwanChina Medical University Hospital; Taipei Veterans General Hospital, Taiwan; National... and other collaboratorsCompleted
-
PharmaEngineCompletedRefractory Solid TumorsTaiwan
-
University Hospital, AntwerpUniversitair Ziekenhuis Brussel; General Hospital Groeninge; AZ Nikolaas; Erasme... and other collaboratorsActive, not recruitingMetastatic Pancreatic Ductal AdenocarcinomaBelgium
-
University of California, San FranciscoNational Cancer Institute (NCI); IpsenCompletedHigh Grade GliomaUnited States
-
Sabine Mueller, MD, PhDPacific Pediatric Neuro-Oncology Consortium; The V Foundation for Cancer ResearchCompletedDiffuse Intrinsic Pontine GliomaUnited States
-
University of California, San FranciscoCompletedGlioblastoma | Gliosarcoma | Anaplastic Astrocytoma | Anaplastic OligodendrogliomaUnited States
-
US Oncology ResearchBristol-Myers Squibb; PfizerActive, not recruiting
-
Bristol-Myers SquibbCompleted